Experimental gel aims to heal blistering skin disease
NCT ID NCT07230223
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This early-stage trial tests a topical treatment called Ev.FV in 20 people with dystrophic epidermolysis bullosa, a genetic condition causing fragile, blistering skin. The treatment uses tiny particles from cells to try to speed wound healing. Researchers will measure wound closure and pain over several weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WOUND HEAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alzahra Hospital
RECRUITINGIsfahan, Iran
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ev.FV (extracellular vesicles applied topically)
What this could lead to
If it works, this could point toward a new topical treatment to help heal wounds in people with epidermolysis bullosa.
What could go wrong
This is an early phase 1/2 trial with only 20 participants, so results may not apply broadly. The treatment may not speed healing or could cause irritation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.